Attitude of infectious diseases physicians in Turkey about HIV pre-exposure prophylaxis: results of an online survey

Pre-exposure prophylaxis (PrEP) is the provision of antiretroviral drugs before HIV exposure to prevent infection for those in whom it is indicated. We conducted an online survey about PrEP in a national sample of infectious diseases physicians in Turkey. They were surveyed from March to April 2019 and they were asked about their attitudes, knowledge and clinical practise about PrEP. Overall, 209 of 2100 (10%) completed the survey, of whom 66.3% were female, 69.5% were specialist and 41.1% were working at education and research hospitals. Most of the participants reported their PrEP knowledge as ‘low’. Men who have sex with men was the most suitable group for PrEP according to participants. 27.9% of them were requested to prescribe PrEP which was to be paid by individuals themselves and 24.2% of the participants had recommended PrEP in their clinical practice. The primary concerns among those who would not recommend PrEP were the possible increase in sexually transmitted infections, the potential low cost-effectiveness of PrEP, the ineffectiveness of PrEP in HIV transmission and the time lost to following-up the individuals taking PrEP. Developing a national guideline would support clinicians in order to change their attitudes and to find answers to their concerns.

[1]  R. Baggaley,et al.  Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV. , 2018, Sexual health.

[2]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[3]  R. Walensky,et al.  The cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil , 2018, Journal of the International AIDS Society.

[4]  A. Nardone,et al.  Healthcare providers' knowledge of, attitudes to and practice of pre‐exposure prophylaxis for HIV infection , 2016, HIV medicine.

[5]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[6]  J. Mellors,et al.  Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? , 2016, Current opinion in HIV and AIDS.

[7]  E. Vittinghoff,et al.  Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. , 2016, JAMA internal medicine.

[8]  V. Patel,et al.  A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians , 2016, Journal of General Internal Medicine.

[9]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[10]  C. B. Hare,et al.  No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. , 2015, Clinical Infectious Diseases.

[11]  L. Grohskopf,et al.  Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States , 2013, Journal of acquired immune deficiency syndromes.

[12]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[13]  S. Hosek,et al.  The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men , 2013, Journal of acquired immune deficiency syndromes.

[14]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[15]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[16]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[17]  Arthur W. Wetzel,et al.  Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) , 2011, PloS one.

[18]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[19]  G. Garnett,et al.  Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness , 2008, AIDS.

[20]  Doug Taylor,et al.  Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.